

February 10, 1969

Dr. Frank Berger  
Wallace Laboratories  
Crandall, New Jersey

Dear Frank,

In reading the latest issue of Drug Research Reports, I noted the report of your lecture at George Washington University, and if the report is correct, I would like to concur in your opinion. For many years I have been among those confused by the usual animal pharmacologic data submitted to investigators as the basis for the selection of drugs for trial. Repeatedly, I have noted that the characteristics proclaimed by one pharmacologist as the basis for the choice of a drug for trial, are disregarded or interpreted differently by another.

You know that we have been actively investigating the role of EEG measures in man as the basis for classifying new drugs. The classification of cyclazocine, fenfluramine, thiothixene, and pinoxepin by these methods have been consistent with the eventual clinical observations. Perhaps the time has come to investigate these data and reports systematically by an industrial laboratory such as your own.

In any case, the report (if correct) is consistent with our observations.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

mf/